# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Moderna announces plans to reduce R&D spending by $1.1 billion by 2027, focusing on ten key products. Analysts highlight ne...
https://www.nbcnews.com/health/health-news/florida-covid-shots-mrna-vaccines-older-adults-rcna170997Even as the Covid wave in F...
B of A Securities analyst Geoff Meacham maintains Moderna (NASDAQ:MRNA) with a Neutral and lowers the price target from $130...
TD Cowen analyst Tyler Van Buren maintains Moderna (NASDAQ:MRNA) with a Hold and lowers the price target from $70 to $60.
RBC Capital analyst Luca Issi maintains Moderna (NASDAQ:MRNA) with a Sector Perform and lowers the price target from $90 to ...